WO2006019300A2 - Immune stimulatory infant nutrition - Google Patents

Immune stimulatory infant nutrition Download PDF

Info

Publication number
WO2006019300A2
WO2006019300A2 PCT/NL2005/000609 NL2005000609W WO2006019300A2 WO 2006019300 A2 WO2006019300 A2 WO 2006019300A2 NL 2005000609 W NL2005000609 W NL 2005000609W WO 2006019300 A2 WO2006019300 A2 WO 2006019300A2
Authority
WO
WIPO (PCT)
Prior art keywords
nutritional composition
acid
composition according
component
group
Prior art date
Application number
PCT/NL2005/000609
Other languages
French (fr)
Other versions
WO2006019300A3 (en
Inventor
Christopher Beermann
Günther Boehm
Bernd Stahl
Original Assignee
N.V. Nutricia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34926246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006019300(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by N.V. Nutricia filed Critical N.V. Nutricia
Priority to BRPI0514498-1A priority Critical patent/BRPI0514498A/en
Priority to NZ553299A priority patent/NZ553299A/en
Priority to CA002577698A priority patent/CA2577698A1/en
Priority to AU2005273099A priority patent/AU2005273099B2/en
Priority to US11/573,939 priority patent/US20080125346A1/en
Priority to JP2007527084A priority patent/JP2008510697A/en
Priority to EP05775170A priority patent/EP1781306A2/en
Publication of WO2006019300A2 publication Critical patent/WO2006019300A2/en
Publication of WO2006019300A3 publication Critical patent/WO2006019300A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a nutritional composition for feeding infants, containing fat, protein, carbohydrate, a nucleotide component and to the use thereof.
  • nucleotide components particularly nucleotides. It was found that by combining nucleotide components with negatively charged non-protein components the bioactive effects of the nucleotide component in nutritional formulations may be enhanced significantly.
  • the present invention provides a nutritional composition containing a nucleotide component; and a non-proteinaceous negatively charged, glycan or glycoconjugate component with a molecular weight between 200 and 20.000 dalton (hereinafter referred to as NCC).
  • NCC non-proteinaceous negatively charged, glycan or glycoconjugate component with a molecular weight between 200 and 20.000 dalton
  • the improved activity is believed to be the result of an improved presentation and delivery of the negatively charged nucleotide component to the epithelial cells, due to interaction of the NCC and the nucleotide component e.g. via hydrogen and salt bridges.
  • the biological active molecular anionic charge of nucleotides is condensed and the molecular distribution of charge is beneficially altered.
  • the present nutritional composition can be even further improved by combining the nucleotide component and NCC with bivalent cations, preferably calcium and/or zinc.
  • the cation will increase proximity of the nucleotide component and the NCC in a liquid environment (e.g. the intestinal tract) by formation of hydrogen/salt bridges, thereby further increasing the interactive effects between the NCC and the nucleotide components.
  • the present invention provides a nutritional composition containing protein, fat and carbohydrate; and a nucleotide component selected from the group consisting of nucleic acid, nucleic acid derivatives, nucleotides, nucleoside polyphosphates, polynucleotides, nucleosides, ribose, desoxyribose, and dinucleosidpolyphosphates
  • Nucleotide component contains a nucleotide component selected from the group consisting of nucleic acid, nucleic acid derivatives, nucleotides, nucleoside polyphosphates, polynucleotides, nucleosides, ribose, desoxyribose, and dinucleosidpolyphosphates (Np x N).
  • Nucleic acids are typically heterocyclic pyrimidine bases cytosine, thymine, uridine and derivatives, like pseudouridine, dihyderouridine, ribothymidine, 4- thiouridine, 3-methylcytidine, N-acetylcytidine, lysidine as well as purine bases adenine and guanosine and derivatives, like 1-methyladenosine, N6- isopentenyladenosine, inosine, N7-methylguansine, N2-dimethylguanosine and wyosine.
  • Nucleosides such as N-glycoside are pyrimidine or purine base glycoconjugates.
  • Preferred nucleotides are phosphoesters of nucleosides, which are monomers or polymers in the form of oligo- or polynucleotides.
  • hydrolysates of desoxyribonucleic acid and ribonucleic acid, t-ribonucleic acid and ribosomes derived from animal milk, animal and plant tissues, yeasts, bifido- and lactobacteria and synthetic molecules are suitable raw material sources.
  • the present composition contains at least one, preferably at least two, even more preferably at least three nucleotides selected from the group consisting of cytidine monophosphate (CMP), guanosine monophosphate (GMP), adenosine monophosphate (AMP), uridine monophosphate (UMP), and inosine monophosphate (IMP).
  • CMP cytidine monophosphate
  • GMP guanosine monophosphate
  • AMP adenosine monophosphate
  • UMP uridine monophosphate
  • IMP inosine monophosphate
  • the present composition contains ribose as a nucleotide component, preferably D-ribose.
  • D(-)Ribose is a pentose sugar that can be purchased as crystalline product. Ribose is a main constituent of nucleic acids.
  • the present composition contains between 0.01 wt.% and 50 wt.% ribose based on dry weight of the product, more preferably between 0.05 and 10 wt.%, even more prefferably between 0.5 and 10 wt.%
  • the present composition preferably comprises between 5 and 100 mg nucleosides and/or between 5 and 100 mg nucleotides per 100 gram dry weight of the composition, more preferably between 5 and 50 mg.
  • the nucleotides and/or nucleosides further stimulate the immune system, acting synergistically with the NCC of the present composition.
  • the present composition contains a negatively charged non-proteineous glycan and 5 glycoconjugate component (NCC) with a molecular weight between 200 and 20.000 dalton.
  • NCC 5 glycoconjugate component
  • the NCC is negatively charged in water with a pH of 7.
  • the negative charge is preferably provided by a carboxylic, phosphate and/or sulphate group, most preferably by a carboxylic group.
  • the NCC has a MW between 1000 and 10 10.000 Dalton.
  • the weight ratio nucleotide component/NCC in the present nutritional composition is preferably between 100 and 0.1.
  • the NCC is selected from the group consisting of glycosphingolipids, acid oligosaccharides, and sialysated oligosaccharides.
  • the sialysated oligosaccharides is sialyllactose and/or disialo-lactoneotertaose (DS-LNT).
  • 15 Glycosphingolipids are typically compounds with a monosaccharide attached directly to a ceramide.
  • the NCC contains a ganglioside (a glycosphingolipid).
  • Gangliosides are typically highly complex oligoglycosylceramides, which contain one or more sialic acid groups (iV-acyl, especially acetyl, derivatives of neuraminic acid, abbreviated 20 to "NANA") in addition to glucose, galactose and galactosamine.
  • sialic acid groups iV-acyl, especially acetyl, derivatives of neuraminic acid, abbreviated 20 to "NANA”
  • buttermilk, egg yolk lecithin are suitable raw material sources of gangliosides. ( Biochemistry, Donald Voet and Judith G. Voet, John Wiley and Sons, Inc NY second edition chapter 23).
  • the present composition preferably contains egg yolk lecithin and/or buttermilk.
  • the present composition contains a ganglioside selected from the group consisting GM3, GMl and GDI .
  • the present composition contains sulfoglycosphingolipids as the NCC.
  • Sulfoglycosphingolipids are sulfate esters of galactosylceramide and lactosylceramide (often referred as "sulfatides” or "lipid sulfates”), with a sulfate group linked to position 3 of the galactosyl moiety.
  • the present composition preferably includes acidic oligosaccharides with a DP from 2 to 100, preferably from 2 to 60.
  • acid or acidic oligosaccharide refers to oligosaccharides comprising at least one acidic group selected from the group consisting of N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group.
  • the acidic oligosaccharide preferably comprises uronic acid units (i.e. uronic acid polymer), more preferably galacturonic acid units.
  • the present composition preferably contains between 0.1 and 10 grams acid oligosaccharides per 100 gram dry weight of the present composition, more preferably between 1 and 6 grams per 100 gram dry weight.
  • R is preferably selected from the group consisting of hydrogen, hydroxy or acid group, preferably hydroxy; and at least one selected from the group consisting of R2, R3, R4 and R5 represents N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group, and the remaining of R2, R3, R4 and R5 representing hydroxy and/or hydrogen.
  • one selected from the group consisting of R2, R3, R4 and R5 represents N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group or phosphoric acid group, and the remaining represent hydroxy and/or hydrogen.
  • R2, R3, R4 and R5 represents free or esterified carboxylic acid and the remaining of R2, R3, R4 and R5 representing hydroxy and/or hydrogen; and n is an integer and refers to a number of hexose units (see also Degree of Polymerisation, below), which may be any hexose unit.
  • n is an integer between 1-5000.
  • the hexose unit(s) is a uronic acid unit.
  • Rl, R2 and R3 represent hydroxy
  • R4 represent hydrogen
  • R5 represents carboxylic acid
  • n is any number between 1 and 250, preferably between 1 and 10 and the hexose unit is galacturonic acid.
  • the acid oligosaccharide has one, preferably two, terminal uronic acid units, which may be free or esterified.
  • the terminal uronic acid unit is selected from the group consisting of galacturonic acid, glucuronic acid, guluronic acid, iduronic acid, mannuronic acid, riburonic acid and alturonic acid. These units may be free or esterified.
  • the terminal hexose unit has a double bond, which is preferably situated between the C4 and C5 position of the terminal hexose unit.
  • one of the terminal hexose units comprises the double bond.
  • the terminal hexose e.g. uronic acid
  • Fig. 2 Preferred terminal hexose acid group
  • R is preferably selected from the group consisting of hydrogen, hydroxy or acid group, preferably hydroxy (see above); and at least one selected from the group consisting of R2, R3, R4 and R5 represents N-acetylneuraminic acid, N- glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group, and the remaining of R2, R3, R4 and R5 representing hydroxy and/or hydrogen.
  • R2, R3, R4 and R5 represents N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group, and the remaining of R2, R3, R4 and R5 represent hydroxy and/or hydrogen. Even more preferably one selected from the group consisting of R2, R3, R4 and R5 represents free or esterified carboxylic acid and the remaining of R2, R3, R4 and R5 represent hydroxy and/or hydrogen; and n is an integer and refers to a number of hexose units (see also Degree of Polymerisation, below), which may be any hexose unit.
  • n is an integer between 1-100 representing the number of hexose units said hexose units preferably being uronic acid, even more preferably being galacturonic acid units.
  • the carboxylic acid groups on these units may be free or (partly) esterified, and are preferably at least partly methylated.
  • R2 and R3 represent hydroxy
  • R4 represent hydrogen
  • R5 represents free or esterified carboxylic acid.
  • the acid oligosaccharides used in the invention are preferably prepared from pectin, pectate, alginate, chondroitine, hyaluronic acids, heparine, heparane, bacterial carbohydrates, sialoglycans, fucoidan, fucooligosaccharides or carrageenan, more preferably from pectin and/or alginate.
  • pectin often biochemically depolymerized is used.
  • pectin depolymerized with pectin lyase is used. Bivalent cation
  • the present nutritional composition preferably contains a bivalent cation.
  • the bivalent cation enhances proximity of the nucleotide component and the NCC, further modifying the charge density and improving biological activity.
  • the present composition contains at least one bivalent cation selected from the group consisting of magnesium, calcium, iron, chromium, manganese, molybdenum, copper and zinc.
  • the present composition contains at least calcium and/or zinc.
  • Zinc is advantageously included in the present composition.
  • Zinc enhances the biological activity of the nucleotides when combined with the present NCC, and also s an essential micronutrient for growth and development of the immune function, particularly for infants.
  • Zinc deficiency impairs overall immune function and resistance to infection.
  • the present composition advantageously comprises zinc, preferably in an amount of 2 to 100 mg zinc per 100 gram dry weight of the present composition, even more preferably between 3 and 25 mg zinc per 100 g dry weight of the present composition.
  • the weight of zinc is calculated as elementary zinc.
  • the present composition contains calcium for improved charge interaction. Calcium is also essential in an infants diet, and hence advantageously included in the present composition. Preferably the present composition contains between 150 and 1000 mg calcium by weight total dry weight of the composition.
  • the present composition can be advantageously used as an infant formula,.
  • the infant formula preferably administered to the infant in liquid form.
  • the term infant includes weaning infants, and toddlers.
  • the present invention relates to an nutritional composition which provides the macronutrients of the infant diet.
  • the present composition preferably contains 30 to 60 en% lipid; 5 to 15 en% protein; and 25 to 65 en% carbohydrate.
  • the present composition contains 43 to 53 en% lipid; 7 to 11 en% protein; and 43 to 53 en% carbohydrate (en% is short for energy percentage and represents the relative amount each constituent contributes to the total caloric value of the preparation).
  • the term "protein” or protein component in this context is the cumulative of protein, polypeptides, peptides and amino acids.
  • the carbohydrate in the present composition is preferably provided largely by lactose, i.e. preferably at least 75 wt.% of total digestible carbohydrate is provided by lactose, preferably at least 90 wt.%.
  • the present composition preferably contains at least 10 wt.% linoleic acid (LA) based on total fatty acids, preferably between 11 and 20 wt.%, more preferably between 12 and 15 wt.%.
  • the present composition preferably contains at least 1 wt.% alpha linolenic acid (ALA) based on total fatty acids, preferably between 1.5 and 4 wt.% ALA, even more preferably between 2 and 2.5 wt.%.
  • the weight ratio LA/ALA is preferably between 2 and 10, preferably between 5 and 7.5.
  • the present composition preferably includes between 0.05 and 5 wt% gamma-linolenic acid (GLA) based on total fatty acids, preferably between 0.1 and 1 wt.%.
  • GLA gamma-linolenic acid
  • STA steraidonic acid
  • the present composition preferably comprises at least one long chain- polyunsaturated fatty acid with 20 or 22 carbon atoms (LCPUFA) in an amount exceeding 0.1 wt.% based on total fatty acids, selected from the group consisting of docosahexaenoic acid (DHA), arachidonic acid (AA) and eicosapentaenoic acid (EPA).
  • DHA docosahexaenoic acid
  • AA arachidonic acid
  • EPA eicosapentaenoic acid
  • the composition contains DHA in an amount exceeding 0.1 wt.% based on total fatty acids; and AA in an amount exceeding 0.1 wt.% based on total fatty acids.
  • At least one LCPUFA of this group is included in an amount between
  • the composition contains AA and DHA, even more preferably AA, DHA and EPA.
  • the AA content preferably does not exceed 5 wt.%, more preferably does not exceed 1 wt.%, most preferably between 0.1 and 0.6 wt.% of the total fatty acids.
  • EPA and/or DHA are advantageously added to balance the action of AA, e.g. reduce the potential pro -inflammatory action of AA metabolites. Excess metabolites from AA may cause inflammation.
  • the present composition preferably comprises AA, EPA and/or DHA, wherein the weight ratio AA/DHA preferably is above 0.25, preferably above 0.5, even more preferably above 1.
  • the ratio AA/DHA is preferably below 25, preferably below 10.
  • the weight ratio AA/EPA is preferably between 1 and 100, more preferably between 5 and 20.
  • the weight ratio EPA/DHA is preferably 1 or lower, more preferably below 0.5.
  • the content of LCPUFA does not exceed 3 wt.% of the total fatty acids as it is desirable to mimic human milk as closely as possible.
  • the present composition preferably contains less than 1 gram omega-3 LCPUFA per 100 gram fatty acids, more preferably between 0.1 and 0.75 gram per 100 gram fatty acids.
  • the omega-6 LCPUFA content preferably does not exceed 2 gram per 100 gram fatty acids and is preferably between 0.1 and 0.75 gram per 100 gram fatty acids.
  • the LCPUFAs and the other fatty acids may be provided as free fatty acids, in triglyceride form, in phospholipid form, or as a mixture of one of more of the above.
  • the present composition advantageously comprises at least one of AA and DHA in phospholipid form, as these reduce the incidence of inflammatory disorders of the intestine.
  • the present composition preferably comprises between 0.1 and 5 mg AA from phospholipid per gram total fat and between 0.1 and 5 mg DHA from phospholipid per gram total fat.
  • the AA and/or DHA are at least partly present in the form of phosphatidylcholine (PC) and/or phosphatidylethanolamine (PE), e.g. AA and/or DHA containing PE and/or PC.
  • the present composition preferably comprises indigestible oligosaccharides with a degree of polymerisation (DP) of between 2 and 100.
  • the oligosaccharides are believed to be important for providing a suitable intestinal environment for improved presentation and charge density of the combination of nucleotide 5 component and NCC.
  • the indigestible oligosaccharides reduce the pH of the intestinal environment, improving biological activity of the nucleotides.
  • the present composition contains 0.1 to 12 grams indigestible oligosaccharides per 100 gram dry weight of the composition, preferably between 3 and 8 grams, more preferably between 5 and 7.5 grams.
  • indigestible oligosaccharides provide the desired effects without causing intestinal discomfort.
  • Suitable indigestible oligosaccharides are not or only partially digested in the intestine by the action of acids or digestive enzymes present in the human upper digestive tract (small intestine and stomach), but are
  • the oligosaccharides are preferably water-soluble (exceeding a solubility of 1 gram oligosaccharide per liter water).
  • the average DP of the present oligosaccharide is preferably below 40, even more preferably below 20.
  • the present composition comprises between 2 and 12 grams oligosaccharides with a DP of 2 to 60, more preferably with a DP of 2 to
  • At least one of the oligosaccharides of the present composition is selected from the group consisting of inulin, fructooligosaccharides, indigestible dextrins, galactooligosaccharides (including 25 transgalactooligosaccharides), xylooligosaccharides, arabinooligosaccharides, glucooligosaccharides, mannooligo-saccharides, lacto-N-neotetraose, fucooligosaccharides (containing at least one fucose saccharide unit), acidic oligosaccharides (e.g. uronic acid oligosaccharides such as pectin oligosaccharides) and mixtures thereof.
  • inulin fructooligosaccharides, indigestible dextrins
  • galactooligosaccharides including 25 transgalactooligosaccharides
  • xylooligosaccharides arab
  • the present composition comprises at least one selected from the group consisting of inulins and fructooligosaccharides and at least one selected from the group consisting of galactooligosaccharides (including transgalactooligosaccharides) and pectin hydrolysate.
  • the present composition comprises 2 to 12 grams oligosaccharides with a DP of 2 to 10 and ⁇ -linked galactose and glucose saccharides, more preferably transgalactooligosaccharides (i.e. [gal] n -glu, wherein n is 2 to 10).
  • the present composition comprises transgalactooligosaccharides (i.e.
  • oligosaccharide is preferably derived from animal milk, a mixture of oligosaccharides derived from animal milk or a fucosylated oligosaccharide (oligosaccharide containing at least one fucose saccharide unit).
  • At least 10 wt.% of the oligosaccharides in the present composition has a DP of 2 to 5 (i.e. 2, 3, 4 and/or 5) and at least 5 wt.% has a DP of 10 to 100.
  • at least 50 wt.%, more preferably at least 75 wt.% of the oligosaccharides have a DP of 2 to 10 (i.e. 2, 3, 4, 5, 6, 7, 8, 9 and/or 10), because these are believed to work throughout the ileum and proximal and middle parts of the colon and because the weight percentage of oligosaccharides that needs to be incorporated in the composition to achieve the desired effect is reduced.
  • the weight ratios i.e. 2, 3, 4 and/or 5
  • oligosaccharides with DP 2 to 5 are both above 1.
  • oligosaccharides with DP 6 to 9 are both above 1.
  • oligosaccharides with DP 10 to 100 are both above 1.
  • Preferably both weight ratios are above 2, even more preferably above 5.
  • the present composition preferably comprises 0.5 to 10 gram galactooligosaccharide with DP between 2 and 10 per 100 gram dry weight of the composition, more preferably between 1 and 5 gram.
  • the preferred galactooligosaccharides is transgalactooligosaccharide, as this best mimics human milk oligosaccharides.
  • the present invention preferably comprises 0.5 to 10 gram fructopolysaccharide with DP between 10 and 60 per 100 gram dry weight of the composition, more preferably between 1 and 5 gram.
  • the term "fructopolysaccliaride” refers to a polysaccharide carbohydrate comprising a chain of at least 10 ⁇ -linked fructose units.
  • the present nutritional composition is preferably in powder or liquid form or in tablet form, wherein said tablet has a weight between 5 and 25 grams.
  • the present composition is provided in powered form as this increases shelf life.
  • the present composition is preferably administered orally in liquid form. Prior to the administration of the present composition, it is preferably admixed with a liquid, preferably water.
  • Stool irregularities e.g. hard stools, insufficient stool volume, diarrhea
  • Stool irregularities is a major problem in many babies and ill subjects that receive liquid foods. It was found that stool problems may be reduced by administering the present composition in liquid form, having an osmolality between 50. and 500 m ⁇ sm/kg, more preferably between 100 and 400 m ⁇ sm/kg, most preferably between 220 and 300 m ⁇ sm/kg.
  • the liquid food does not have an excessive caloric density as this causes significant intestinal stress.
  • the formula needs to provide sufficient calories to feed the infant.
  • the liquid food preferably has a caloric density between 0.5 and 0.9 kcal/ml, preferably between 0.6 and 0.8 kcal/ml.
  • the present composition is advantageously administered to infants with the age between 0 and 2 years.
  • the present composition can also be advantageously used in a method for providing the nutritional requirements of a premature infant (an infant born before 37 weeks gestation).
  • the present invention provides a method for feeding infants with an age between 0 and 30 day.
  • the present composition can be advantageously used to treat or prevent diseases wherein a comprised immune system and/or intestinal barrier immaturity is underlying the development of the course of the disease.
  • the present composition can thus be advantageously used to treat or prevent diarrhea or allergy, particularly in infants with an age between 0 and 2.
  • the present composition is particularly suitable for the treatment and/or prevention of allergic rhinitis, allergic conjunctivitis, allergic dermatitis, atopic dermatitis and/or food allergy.
  • the present method provides for a method for the treatment and/or prevention of infections, said method comprising administering the present composition.
  • Example 1 Infant nutrition
  • a liquid infant nutrition prepared by admixing 13.9 g powder with water to yield 100 ml final product, said liquid product comprising per 100 ml:
  • Fibre 0.8 g (containing 0.05 g fructopolysaccharide (Raftiline HPTM, Orafti,
  • Uridine-5-monophosphate 0.82 mg Adenosine-5-monophosphate; 0.20 mg Guanosine-5-monophosphate; 0.34 mg Inosine-5monophosphate.
  • NCC 0.55 mg Uridine-5-monophosphate; 0.82 mg Adenosine-5-monophosphate; 0.20 mg Guanosine-5-monophosphate; 0.34 mg Inosine-5monophosphate.
  • composition further contains choline (6 mg/100 ml) and taurine (6.3 mg/100 ml); minerals and trace elements and vitamins in amounts in compliance with the international guidelines for infant milk formula.
  • Example 2 Composition according to example 1, wherein the nucleotide component is replaced by dinucleosidporyphosphates (NpxN) Gp4G
  • composition according to example 1, wherein the nucleotide component is an DNA/RNA oligomers extract
  • composition according to example 1 comprising 1 wt.% D-ribose based on total dry weight of the composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pediatric Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a nutritional composition containing protein, fat and carbohydrate; and a. a nucleotide component selected from the group consisting of nucleic acid, nucleic acid derivatives, nucleotides, nucleoside polyphosphates, polynucleotides, nucleosides, ribose, desoxyribose, and dinucleosidpolyphosphates (NpXN); and b. a non-proteinaceous negatively charged, glycan or glycoconjugate component with a molecular weight between 200 and 20.000 dalton. The present nutritional composition is particularly suited for feeding infants as it mimics the protective effects of human milk, in particular against allergies and infections.

Description

INFANT FORMULA
FIELD OF THE INVENTION
The present invention relates to a nutritional composition for feeding infants, containing fat, protein, carbohydrate, a nucleotide component and to the use thereof.
BACKGROUND OF THE INVENTION
Breastfeeding optimally supports the development of the infant and protects against infections and allergies. However, not all infants are in the position to receive human milk. It is therefore a continuing aim to provide infant formula, which simulates the functions of human milk. In addition to the desired compositional similarity between infant formula and human milk, it is also particularly desirable to mimic the protective effects of human milk, in particular protection against allergies and infections.
SUMMARY OF THE INVENTION
The present inventors have recognized that the molecular structure and density of charge of nucleotides is an important factor for the bioactivity of nucleotide components, particularly nucleotides. It was found that by combining nucleotide components with negatively charged non-protein components the bioactive effects of the nucleotide component in nutritional formulations may be enhanced significantly.
Hence, the present invention provides a nutritional composition containing a nucleotide component; and a non-proteinaceous negatively charged, glycan or glycoconjugate component with a molecular weight between 200 and 20.000 dalton (hereinafter referred to as NCC).
The present nutritional composition is particularly effective in:
• Enhancing immune cell proliferation, improving the development of T-lymphocyte sub populations, and enhancing the antibody response;
• Stimulating the development of the immune system of neonates β Stimulating the development of the nerve system of neonates
• Stimulating the neonatal development and repair of the gastrointestinal tract after surgery or disease
* Modulating the gutflora, Stimulating the synthesis of long-chain polyunsaturated fatty acids
• Providing anti-infective, antibacterial/viral effects
Without wishing to be bound by theory, the improved activity is believed to be the result of an improved presentation and delivery of the negatively charged nucleotide component to the epithelial cells, due to interaction of the NCC and the nucleotide component e.g. via hydrogen and salt bridges. The biological active molecular anionic charge of nucleotides is condensed and the molecular distribution of charge is beneficially altered.
The present nutritional composition can be even further improved by combining the nucleotide component and NCC with bivalent cations, preferably calcium and/or zinc. The cation will increase proximity of the nucleotide component and the NCC in a liquid environment (e.g. the intestinal tract) by formation of hydrogen/salt bridges, thereby further increasing the interactive effects between the NCC and the nucleotide components.
DETAILED DESCRIPTION
The present invention provides a nutritional composition containing protein, fat and carbohydrate; and a nucleotide component selected from the group consisting of nucleic acid, nucleic acid derivatives, nucleotides, nucleoside polyphosphates, polynucleotides, nucleosides, ribose, desoxyribose, and dinucleosidpolyphosphates
, (NpxN); and a non-proteinaceous negatively charged, glycan or glycoconjugate component with a molecular weight between 200 and 20.000 dalton
Nucleotide component The present composition contains a nucleotide component selected from the group consisting of nucleic acid, nucleic acid derivatives, nucleotides, nucleoside polyphosphates, polynucleotides, nucleosides, ribose, desoxyribose, and dinucleosidpolyphosphates (NpxN).
Nucleic acids are typically heterocyclic pyrimidine bases cytosine, thymine, uridine and derivatives, like pseudouridine, dihyderouridine, ribothymidine, 4- thiouridine, 3-methylcytidine, N-acetylcytidine, lysidine as well as purine bases adenine and guanosine and derivatives, like 1-methyladenosine, N6- isopentenyladenosine, inosine, N7-methylguansine, N2-dimethylguanosine and wyosine. Nucleosides such as N-glycoside are pyrimidine or purine base glycoconjugates. Preferred nucleotides are phosphoesters of nucleosides, which are monomers or polymers in the form of oligo- or polynucleotides. For this application especially hydrolysates of desoxyribonucleic acid and ribonucleic acid, t-ribonucleic acid and ribosomes derived from animal milk, animal and plant tissues, yeasts, bifido- and lactobacteria and synthetic molecules are suitable raw material sources. ( Biochemistry, Donald Voet and Judith G. Voet, John Wiley and Sons, Inc NY second edition chapter 28, pp 849)
Preferably, the present composition contains at least one, preferably at least two, even more preferably at least three nucleotides selected from the group consisting of cytidine monophosphate (CMP), guanosine monophosphate (GMP), adenosine monophosphate (AMP), uridine monophosphate (UMP), and inosine monophosphate (IMP).
In a further preferred embodiment the present composition contains ribose as a nucleotide component, preferably D-ribose. D(-)Ribose is a pentose sugar that can be purchased as crystalline product. Ribose is a main constituent of nucleic acids. Preferably the present composition contains between 0.01 wt.% and 50 wt.% ribose based on dry weight of the product, more preferably between 0.05 and 10 wt.%, even more prefferably between 0.5 and 10 wt.%
The present composition preferably comprises between 5 and 100 mg nucleosides and/or between 5 and 100 mg nucleotides per 100 gram dry weight of the composition, more preferably between 5 and 50 mg. The nucleotides and/or nucleosides further stimulate the immune system, acting synergistically with the NCC of the present composition.
Negatively charged component (NCC)
The present composition contains a negatively charged non-proteineous glycan and 5 glycoconjugate component (NCC) with a molecular weight between 200 and 20.000 dalton.
The NCC is negatively charged in water with a pH of 7. The negative charge is preferably provided by a carboxylic, phosphate and/or sulphate group, most preferably by a carboxylic group. Preferably the NCC has a MW between 1000 and 10 10.000 Dalton. The weight ratio nucleotide component/NCC in the present nutritional composition is preferably between 100 and 0.1.
Preferably the NCC is selected from the group consisting of glycosphingolipids, acid oligosaccharides, and sialysated oligosaccharides. Preferably the sialysated oligosaccharides is sialyllactose and/or disialo-lactoneotertaose (DS-LNT). 15 Glycosphingolipids are typically compounds with a monosaccharide attached directly to a ceramide.
Preferably the NCC contains a ganglioside (a glycosphingolipid). Gangliosides are typically highly complex oligoglycosylceramides, which contain one or more sialic acid groups (iV-acyl, especially acetyl, derivatives of neuraminic acid, abbreviated 20 to "NANA") in addition to glucose, galactose and galactosamine. For this application, especially buttermilk, egg yolk lecithin are suitable raw material sources of gangliosides. ( Biochemistry, Donald Voet and Judith G. Voet, John Wiley and Sons, Inc NY second edition chapter 23). Hence the present composition preferably contains egg yolk lecithin and/or buttermilk.
25 In a particularly preferred embodiment the present composition contains a ganglioside selected from the group consisting GM3, GMl and GDI .
In a further preferred embodiment, the present composition contains sulfoglycosphingolipids as the NCC. Sulfoglycosphingolipids are sulfate esters of galactosylceramide and lactosylceramide (often referred as "sulfatides" or "lipid sulfates"), with a sulfate group linked to position 3 of the galactosyl moiety.
Acidic oligosaccharides
The present composition preferably includes acidic oligosaccharides with a DP from 2 to 100, preferably from 2 to 60. The term acid or acidic oligosaccharide refers to oligosaccharides comprising at least one acidic group selected from the group consisting of N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group. The acidic oligosaccharide preferably comprises uronic acid units (i.e. uronic acid polymer), more preferably galacturonic acid units. The present composition preferably contains between 0.1 and 10 grams acid oligosaccharides per 100 gram dry weight of the present composition, more preferably between 1 and 6 grams per 100 gram dry weight.
Structure I: Polymeric acid oligosaccharide
Figure imgf000006_0001
wherein:
R is preferably selected from the group consisting of hydrogen, hydroxy or acid group, preferably hydroxy; and at least one selected from the group consisting of R2, R3, R4 and R5 represents N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group, and the remaining of R2, R3, R4 and R5 representing hydroxy and/or hydrogen. Preferably one selected from the group consisting of R2, R3, R4 and R5 represents N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group or phosphoric acid group, and the remaining represent hydroxy and/or hydrogen. Even more preferably one selected from the group consisting of R2, R3, R4 and R5 represents free or esterified carboxylic acid and the remaining of R2, R3, R4 and R5 representing hydroxy and/or hydrogen; and n is an integer and refers to a number of hexose units (see also Degree of Polymerisation, below), which may be any hexose unit. Suitably n is an integer between 1-5000. Preferably the hexose unit(s) is a uronic acid unit.
Most preferably Rl, R2 and R3 represent hydroxy, R4 represent hydrogen, R5 represents carboxylic acid, n is any number between 1 and 250, preferably between 1 and 10 and the hexose unit is galacturonic acid.
The detection, measurement and analyses of the preferred acid oligosaccharides as used in the present method are given in applicants earlier patent application relating to acid oligosaccharides, i.e. WO 0/160378.
Preferably, the acid oligosaccharide has one, preferably two, terminal uronic acid units, which may be free or esterified. Preferably the terminal uronic acid unit is selected from the group consisting of galacturonic acid, glucuronic acid, guluronic acid, iduronic acid, mannuronic acid, riburonic acid and alturonic acid. These units may be free or esterified. In an even more preferred embodiment, the terminal hexose unit has a double bond, which is preferably situated between the C4 and C5 position of the terminal hexose unit. Preferably one of the terminal hexose units comprises the double bond. The terminal hexose (e.g. uronic acid) preferably has a structure according to Fig.2.
Fig. 2: Preferred terminal hexose acid group
Figure imgf000007_0001
wherein;
R is preferably selected from the group consisting of hydrogen, hydroxy or acid group, preferably hydroxy (see above); and at least one selected from the group consisting of R2, R3, R4 and R5 represents N-acetylneuraminic acid, N- glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group, and the remaining of R2, R3, R4 and R5 representing hydroxy and/or hydrogen. Preferably one selected from the group consisting of R2, R3, R4 and R5 represents N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group, and the remaining of R2, R3, R4 and R5 represent hydroxy and/or hydrogen. Even more preferably one selected from the group consisting of R2, R3, R4 and R5 represents free or esterified carboxylic acid and the remaining of R2, R3, R4 and R5 represent hydroxy and/or hydrogen; and n is an integer and refers to a number of hexose units (see also Degree of Polymerisation, below), which may be any hexose unit. Suitably n is an integer between 1-100 representing the number of hexose units said hexose units preferably being uronic acid, even more preferably being galacturonic acid units. The carboxylic acid groups on these units may be free or (partly) esterified, and are preferably at least partly methylated.
Most preferably, R2 and R3 represent hydroxy, R4 represent hydrogen and R5 represents free or esterified carboxylic acid.
The acid oligosaccharides used in the invention are preferably prepared from pectin, pectate, alginate, chondroitine, hyaluronic acids, heparine, heparane, bacterial carbohydrates, sialoglycans, fucoidan, fucooligosaccharides or carrageenan, more preferably from pectin and/or alginate. Preferably pectin, often biochemically depolymerized is used. Most preferably pectin depolymerized with pectin lyase is used. Bivalent cation
The present nutritional composition preferably contains a bivalent cation. The bivalent cation enhances proximity of the nucleotide component and the NCC, further modifying the charge density and improving biological activity. Preferably the present composition contains at least one bivalent cation selected from the group consisting of magnesium, calcium, iron, chromium, manganese, molybdenum, copper and zinc. Preferably the present composition contains at least calcium and/or zinc.
Zinc is advantageously included in the present composition. Zinc enhances the biological activity of the nucleotides when combined with the present NCC, and also s an essential micronutrient for growth and development of the immune function, particularly for infants. Zinc deficiency impairs overall immune function and resistance to infection. Hence, the present composition advantageously comprises zinc, preferably in an amount of 2 to 100 mg zinc per 100 gram dry weight of the present composition, even more preferably between 3 and 25 mg zinc per 100 g dry weight of the present composition. The weight of zinc is calculated as elementary zinc.
In a further preferred embodiment, the present composition contains calcium for improved charge interaction. Calcium is also essential in an infants diet, and hence advantageously included in the present composition. Preferably the present composition contains between 150 and 1000 mg calcium by weight total dry weight of the composition.
Macronutrients
The present composition can be advantageously used as an infant formula,. The infant formula preferably administered to the infant in liquid form. The term infant includes weaning infants, and toddlers.
In a preferred embodiment the present invention relates to an nutritional composition which provides the macronutrients of the infant diet. Hence, the present composition preferably contains 30 to 60 en% lipid; 5 to 15 en% protein; and 25 to 65 en% carbohydrate. Preferably, the present composition contains 43 to 53 en% lipid; 7 to 11 en% protein; and 43 to 53 en% carbohydrate (en% is short for energy percentage and represents the relative amount each constituent contributes to the total caloric value of the preparation). The term "protein" or protein component in this context is the cumulative of protein, polypeptides, peptides and amino acids. The carbohydrate in the present composition is preferably provided largely by lactose, i.e. preferably at least 75 wt.% of total digestible carbohydrate is provided by lactose, preferably at least 90 wt.%.
Essential fatty acids content
The present composition preferably contains at least 10 wt.% linoleic acid (LA) based on total fatty acids, preferably between 11 and 20 wt.%, more preferably between 12 and 15 wt.%. The present composition preferably contains at least 1 wt.% alpha linolenic acid (ALA) based on total fatty acids, preferably between 1.5 and 4 wt.% ALA, even more preferably between 2 and 2.5 wt.%. To reduce intestinal stress, the weight ratio LA/ALA is preferably between 2 and 10, preferably between 5 and 7.5. The present composition preferably includes between 0.05 and 5 wt% gamma-linolenic acid (GLA) based on total fatty acids, preferably between 0.1 and 1 wt.%. Preferably the present composition contains between 0.05 and 5 wt% steraidonic acid (STA) preferably more preferably between 0.1 and 1 wt.%.
Long chain-polvunsaturated fatty acid content
The present composition preferably comprises at least one long chain- polyunsaturated fatty acid with 20 or 22 carbon atoms (LCPUFA) in an amount exceeding 0.1 wt.% based on total fatty acids, selected from the group consisting of docosahexaenoic acid (DHA), arachidonic acid (AA) and eicosapentaenoic acid (EPA). Preferably the composition contains DHA in an amount exceeding 0.1 wt.% based on total fatty acids; and AA in an amount exceeding 0.1 wt.% based on total fatty acids.
Preferably at least one LCPUFA of this group is included in an amount between
0.15 and 1 wt.% based on total fatty acid content of the composition. Preferably at least two of these LCPUFA's are present in an amount of between 0.15 and 1 wt.% based on total fatty acid content of the composition. Preferably the composition contains AA and DHA, even more preferably AA, DHA and EPA.
The AA content preferably does not exceed 5 wt.%, more preferably does not exceed 1 wt.%, most preferably between 0.1 and 0.6 wt.% of the total fatty acids. In the present composition, EPA and/or DHA are advantageously added to balance the action of AA, e.g. reduce the potential pro -inflammatory action of AA metabolites. Excess metabolites from AA may cause inflammation. Hence, the present composition preferably comprises AA, EPA and/or DHA, wherein the weight ratio AA/DHA preferably is above 0.25, preferably above 0.5, even more preferably above 1. The ratio AA/DHA is preferably below 25, preferably below 10. The weight ratio AA/EPA is preferably between 1 and 100, more preferably between 5 and 20. The weight ratio EPA/DHA is preferably 1 or lower, more preferably below 0.5.
In a preferred embodiment, the content of LCPUFA does not exceed 3 wt.% of the total fatty acids as it is desirable to mimic human milk as closely as possible. For the same reason, the present composition preferably contains less than 1 gram omega-3 LCPUFA per 100 gram fatty acids, more preferably between 0.1 and 0.75 gram per 100 gram fatty acids. The omega-6 LCPUFA content preferably does not exceed 2 gram per 100 gram fatty acids and is preferably between 0.1 and 0.75 gram per 100 gram fatty acids.
The LCPUFAs and the other fatty acids may be provided as free fatty acids, in triglyceride form, in phospholipid form, or as a mixture of one of more of the above. The present composition advantageously comprises at least one of AA and DHA in phospholipid form, as these reduce the incidence of inflammatory disorders of the intestine. The present composition preferably comprises between 0.1 and 5 mg AA from phospholipid per gram total fat and between 0.1 and 5 mg DHA from phospholipid per gram total fat. Preferably the AA and/or DHA are at least partly present in the form of phosphatidylcholine (PC) and/or phosphatidylethanolamine (PE), e.g. AA and/or DHA containing PE and/or PC.
Oligosaccharides The present composition preferably comprises indigestible oligosaccharides with a degree of polymerisation (DP) of between 2 and 100. The oligosaccharides are believed to be important for providing a suitable intestinal environment for improved presentation and charge density of the combination of nucleotide 5 component and NCC. The indigestible oligosaccharides reduce the pH of the intestinal environment, improving biological activity of the nucleotides. Preferably, the present composition contains 0.1 to 12 grams indigestible oligosaccharides per 100 gram dry weight of the composition, preferably between 3 and 8 grams, more preferably between 5 and 7.5 grams. After reconstitution of
10 the powder in liquid and administration of the liquid formula to the infant, these amounts of indigestible oligosaccharides provide the desired effects without causing intestinal discomfort. Suitable indigestible oligosaccharides are not or only partially digested in the intestine by the action of acids or digestive enzymes present in the human upper digestive tract (small intestine and stomach), but are
15 fermentable by the human intestinal flora. The oligosaccharides are preferably water-soluble (exceeding a solubility of 1 gram oligosaccharide per liter water). The average DP of the present oligosaccharide is preferably below 40, even more preferably below 20. Optimally, the present composition comprises between 2 and 12 grams oligosaccharides with a DP of 2 to 60, more preferably with a DP of 2 to
20 10 (i.e. the sum of the weights of those oligosaccharides with a DP of 2, 3, 4, 5, 6, 7, 8, 9 and 10).
According to a further embodiment at least one of the oligosaccharides of the present composition is selected from the group consisting of inulin, fructooligosaccharides, indigestible dextrins, galactooligosaccharides (including 25 transgalactooligosaccharides), xylooligosaccharides, arabinooligosaccharides, glucooligosaccharides, mannooligo-saccharides, lacto-N-neotetraose, fucooligosaccharides (containing at least one fucose saccharide unit), acidic oligosaccharides (e.g. uronic acid oligosaccharides such as pectin oligosaccharides) and mixtures thereof.
30 Preferably, the present composition comprises at least one selected from the group consisting of inulins and fructooligosaccharides and at least one selected from the group consisting of galactooligosaccharides (including transgalactooligosaccharides) and pectin hydrolysate. In a particularly preferred embodiment, the present composition comprises 2 to 12 grams oligosaccharides with a DP of 2 to 10 and β-linked galactose and glucose saccharides, more preferably transgalactooligosaccharides (i.e. [gal]n -glu, wherein n is 2 to 10). In a particularly preferred embodiment, the present composition comprises transgalactooligosaccharides (i.e. [gal]n -glu, wherein n is 2 to 10), pectin hydrolysate and at least one selected from the group consisting of fructooligosaccharides and inulin. The present oligosaccharide is preferably derived from animal milk, a mixture of oligosaccharides derived from animal milk or a fucosylated oligosaccharide (oligosaccharide containing at least one fucose saccharide unit).
For further improvement of gut maturation over the whole area of the colon, preferably at least 10 wt.% of the oligosaccharides in the present composition has a DP of 2 to 5 (i.e. 2, 3, 4 and/or 5) and at least 5 wt.% has a DP of 10 to 100. Preferably at least 50 wt.%, more preferably at least 75 wt.% of the oligosaccharides have a DP of 2 to 10 (i.e. 2, 3, 4, 5, 6, 7, 8, 9 and/or 10), because these are believed to work throughout the ileum and proximal and middle parts of the colon and because the weight percentage of oligosaccharides that needs to be incorporated in the composition to achieve the desired effect is reduced. Preferably, the weight ratios:
(oligosaccharides with DP 2 to 5) : (oligosaccharides with DP 6 to 9); and (oligosaccharides with DP 10 to 100) : (oligosaccharides with DP 6 to 9) are both above 1. Preferably both weight ratios are above 2, even more preferably above 5.
The present composition preferably comprises 0.5 to 10 gram galactooligosaccharide with DP between 2 and 10 per 100 gram dry weight of the composition, more preferably between 1 and 5 gram. The preferred galactooligosaccharides is transgalactooligosaccharide, as this best mimics human milk oligosaccharides. The present invention preferably comprises 0.5 to 10 gram fructopolysaccharide with DP between 10 and 60 per 100 gram dry weight of the composition, more preferably between 1 and 5 gram. The term "fructopolysaccliaride" refers to a polysaccharide carbohydrate comprising a chain of at least 10 β-linked fructose units.
Liquid
The present nutritional composition is preferably in powder or liquid form or in tablet form, wherein said tablet has a weight between 5 and 25 grams. Preferably, the present composition is provided in powered form as this increases shelf life. The present composition is preferably administered orally in liquid form. Prior to the administration of the present composition, it is preferably admixed with a liquid, preferably water.
Stool irregularities (e.g. hard stools, insufficient stool volume, diarrhea) is a major problem in many babies and ill subjects that receive liquid foods. It was found that stool problems may be reduced by administering the present composition in liquid form, having an osmolality between 50. and 500 mθsm/kg, more preferably between 100 and 400 mθsm/kg, most preferably between 220 and 300 mθsm/kg.
In view of the above diarrhea problem, it is also important that the liquid food does not have an excessive caloric density as this causes significant intestinal stress. However, the formula needs to provide sufficient calories to feed the infant. Hence, the liquid food preferably has a caloric density between 0.5 and 0.9 kcal/ml, preferably between 0.6 and 0.8 kcal/ml.
Application
The present composition is advantageously administered to infants with the age between 0 and 2 years. The present composition can also be advantageously used in a method for providing the nutritional requirements of a premature infant (an infant born before 37 weeks gestation). In a preferred embodiment, the present invention provides a method for feeding infants with an age between 0 and 30 day.
The present composition can be advantageously used to treat or prevent diseases wherein a comprised immune system and/or intestinal barrier immaturity is underlying the development of the course of the disease. The present composition can thus be advantageously used to treat or prevent diarrhea or allergy, particularly in infants with an age between 0 and 2. The present composition is particularly suitable for the treatment and/or prevention of allergic rhinitis, allergic conjunctivitis, allergic dermatitis, atopic dermatitis and/or food allergy. In a preferred embodiment, the present method provides for a method for the treatment and/or prevention of infections, said method comprising administering the present composition.
The invention is further illustrated by means of the following examples:
Example 1 : Infant nutrition
A liquid infant nutrition, prepared by admixing 13.9 g powder with water to yield 100 ml final product, said liquid product comprising per 100 ml:
Energy: 66 kcal
Protein: 8 en%
1.3 g (containing 0.6 g casein; 0.8 g whey; 0.072 g L-arginine)
Digestible carbohydrates: 44 en%
7.4 g (containing 7.3 g lactose)
Fat: 48 en%
3.5 g (containing 0.41 g linoleic acid ; 0.08 g α-linolenic acid; 0.012 g arachidonic acid; 0.002 g eicosapentanoic acid; 0.006 g docosahexaenoic acid; 1.4 g oleic acid; )
Fibre: 0.8 g (containing 0.05 g fructopolysaccharide (Raftiline HP™, Orafti,
Tienen, Belgium); 0.55 g transgalactooligosaccharides (Vivinal-GOS™ (Borculo Domo Ingredients, Netherlands); 0.20 g pectin hydrolysate prepared as described in EP 1373543, example 1.
Nucleotide components: 0.89 mg Cytidine-5-monophosphate;
0.55 mg Uridine-5-monophosphate; 0.82 mg Adenosine-5-monophosphate; 0.20 mg Guanosine-5-monophosphate; 0.34 mg Inosine-5monophosphate. NCC:
5 mg GM3, 50 mg pectin derived oligosaccharides with DP between 5 and 50, and 20 mg sialyllactose Calcium:
53 mg calcium
Zinc:
0.8 mg zinc Osmolarity: 300 mOsmol/1
The composition further contains choline (6 mg/100 ml) and taurine (6.3 mg/100 ml); minerals and trace elements and vitamins in amounts in compliance with the international guidelines for infant milk formula.
Example 2: Composition according to example 1, wherein the nucleotide component is replaced by dinucleosidporyphosphates (NpxN) Gp4G
Example 3 :
Composition according to example 1, wherein the nucleotide component is an DNA/RNA oligomers extract
Example 4
Composition according to example 1, comprising 1 wt.% D-ribose based on total dry weight of the composition.

Claims

1. Nutritional composition containing protein, fat and carbohydrate; and a. a nucleotide component selected from the group consisting of nucleic acid, nucleic acid derivatives, nucleotides, nucleoside polyphosphates, polynucleotides, nucleosides, ribose, desoxyribose, and dinucleosidpolyphosphates (NpxN); and b. a non-proteinaceous negatively charged, glycan or glycoconjugate component with a molecular weight between 200 and 20.000 dalton.
2. Nutritional composition according to claim 1, wherein component b. has a molecular weight between 1000 and 10.000 dalton.
3. Nutritional composition according to claim 1 or 2, wherein the nutritional composition contains 5 to 15 en% protein; 30 to 60 en% fat; and 25 to 65 en% carbohydrate.
4. Nutritional composition according to any one of the preceding claims, wherein the nutritional composition comprises between 5 and 100 mg nucleotides and/or between 5 and 100 mg nucleosides per 1 OjO gram dry weight of the composition.
5. Nutritional composition according to any one of claims 1-3, wherein the nucleotide component is ribose.
6. Nutritional composition according to any one of the preceding claims containing between 150 and 1000 mg calcium and/or 2 to 100 mg zinc, each per 100 gram dry weight of the present composition.
7. Nutritional composition according to any one of the preceding claims wherein the negatively charged component is selected from the group consisting of acidic oligosaccharides and gangliosides.
8. Nutritional composition according to any one of the preceding claims, wherein the negatively charged component is a polygalacturonic acid with a DP between 2 and 100, preferably pectin hydrolysate.
9. Nutritional composition according to any one of claims 1-7, wherein the negatively charged component is a ganglioside.
10. Nutritional composition according to any one of the preceding claimsfor use as a medicament.
11. Use of a nutritional composition according to any one of claims 1-9, for the manufacture of a composition for use in a method for providing nutrition to an infant, said method comprising administering the nutritional composition
12. Use of a nutritional composition as defined in anyone of claims 1 - 9 for the manufacture of a composition for administration to a mammal for the treatment and/or prevention of an inflammatory disease, diarrhea, eczema and/or atopic dermatitis.
13. Use according to claim 12, wherein the inflammatory disease is allergy.
14. Use according to any one of claims 12 or 13, wherein the mammal is a human infant.
PCT/NL2005/000609 2004-08-20 2005-08-22 Immune stimulatory infant nutrition WO2006019300A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BRPI0514498-1A BRPI0514498A (en) 2004-08-20 2005-08-22 nutritional composition and use of nutritional composition
NZ553299A NZ553299A (en) 2004-08-20 2005-08-22 Immune stimulatory infant formula with nucleotides and a negatively charged glycan or glycoconjugate
CA002577698A CA2577698A1 (en) 2004-08-20 2005-08-22 Infant formula
AU2005273099A AU2005273099B2 (en) 2004-08-20 2005-08-22 Immune stimulatory infant nutrition
US11/573,939 US20080125346A1 (en) 2004-08-20 2005-08-22 Infant Formula
JP2007527084A JP2008510697A (en) 2004-08-20 2005-08-22 Infant formula
EP05775170A EP1781306A2 (en) 2004-08-20 2005-08-22 Immune stimulatory infant nutrition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04019856A EP1634599A1 (en) 2004-08-20 2004-08-20 Iimmune stimulatory infant nutrition
EP04019856.6 2004-08-20

Publications (2)

Publication Number Publication Date
WO2006019300A2 true WO2006019300A2 (en) 2006-02-23
WO2006019300A3 WO2006019300A3 (en) 2006-06-01

Family

ID=34926246

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2005/008999 WO2006018314A2 (en) 2004-08-20 2005-08-19 Immune stimulatory infant nutrition
PCT/NL2005/000609 WO2006019300A2 (en) 2004-08-20 2005-08-22 Immune stimulatory infant nutrition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/008999 WO2006018314A2 (en) 2004-08-20 2005-08-19 Immune stimulatory infant nutrition

Country Status (15)

Country Link
US (3) US8114441B2 (en)
EP (3) EP1634599A1 (en)
JP (2) JP4965444B2 (en)
CN (3) CN101766228B (en)
AT (1) ATE427112T1 (en)
AU (2) AU2005274266B2 (en)
BR (2) BRPI0514526A (en)
CA (2) CA2576042C (en)
DE (1) DE602005013679D1 (en)
ES (1) ES2322380T3 (en)
NZ (2) NZ553248A (en)
PL (1) PL1781307T3 (en)
RU (2) RU2426549C2 (en)
UA (1) UA88918C2 (en)
WO (2) WO2006018314A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073177A2 (en) * 2005-12-23 2007-06-28 N.V. Nutricia Composition comprising polyunsaturated fatty acids for improving membrane composition
JP2007222128A (en) * 2006-02-27 2007-09-06 Pola Chem Ind Inc Food composition
WO2007114696A1 (en) * 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
EP2241196A3 (en) * 2005-04-21 2010-11-17 N.V. Nutricia Nutritional supplement comprising oligosaccharides and cysteine for treating hiv
US20110009349A1 (en) * 2007-10-19 2011-01-13 Fonterra Co-Operative Group Limited Methods of maintaining or increasing growth or cognitive development
WO2011135564A1 (en) 2010-04-26 2011-11-03 Enzymotec Ltd. Methods and lipid compositions for promoting development of gut flora
WO2012092153A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
RU2475031C2 (en) * 2007-05-18 2013-02-20 Мид Джонсон Нутришен Компани Acidified liquid additive to human milk
US20140187513A1 (en) * 2007-03-13 2014-07-03 N.V. Nutricia Method of improving skills with a composition comprising non-digestible saccharide
US10251899B2 (en) * 2007-10-08 2019-04-09 Mead Johnson Nutrition Company Method for improving stool characteristics in infants

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1629850T5 (en) * 2004-08-24 2013-09-30 Nutricia Nv Nutritional composition comprising indigestible transgalactooligosaccharides and digestible galactose saccharides
US7749545B2 (en) 2005-03-18 2010-07-06 Sakura Properties, Llc Fucoidan compositions and methods for dietary and nutritional supplements
US20060210697A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Infant formula composition
US20060210524A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Skin care composition
US20060210515A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Hair growth formula
EP1888081B1 (en) * 2005-05-23 2016-12-28 Massachusetts Institute of Technology Compositions containing pufa and methods of use thereof
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
WO2008054192A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
PT1962823E (en) * 2005-12-23 2015-06-29 Nutricia Nv Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
WO2007096148A1 (en) * 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
PL2164349T3 (en) 2006-08-04 2015-03-31 Shs Int Ltd Protein free formula
US20080145506A1 (en) * 2006-12-18 2008-06-19 Bodybio, Inc. Food compositions and products containing balanced ratio of essential fatty acids
WO2008115046A1 (en) * 2007-03-22 2008-09-25 N.V. Nutricia Cereal-based infant nutrition with fibre
MX2010002978A (en) * 2007-09-17 2010-06-09 Nutricia Nv Nutritional formulation with high energy content.
CN103202353A (en) * 2007-11-01 2013-07-17 恩兹默泰克有限公司 Lipid mixture for infant nutrition
WO2009057994A1 (en) * 2007-11-02 2009-05-07 N.V. Nutricia Unit dosage for brain health
WO2009075564A1 (en) * 2007-12-10 2009-06-18 N.V. Nutricia Paediatric fibre mixture
CN101909632A (en) * 2008-01-04 2010-12-08 雀巢产品技术援助有限公司 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions
EP2130440A1 (en) * 2008-06-06 2009-12-09 N.V. Nutricia Inhibiting E. sakazakii growth
MX357863B (en) * 2009-01-19 2018-07-26 Nestec Sa Nutritional composition for infants.
WO2010110649A1 (en) * 2009-03-24 2010-09-30 N.V. Nutricia Stage 1 and stage 2 infant formula
WO2010147456A1 (en) * 2009-06-19 2010-12-23 N.V. Nutricia Inhibition of nfk-b mediated virus replication with specific oligosaccharides
CA2787318A1 (en) * 2010-01-21 2011-07-28 Paul Bradley Addis Composition for perinatal and neonatal stroke
JP5996837B2 (en) * 2010-05-28 2016-09-21 小林製薬株式会社 Influenza virus infection inhibitor
CN101978841B (en) * 2010-08-31 2013-04-10 浙江贝因美科工贸股份有限公司 Protein allergy-resisting and nutritious infant formula milk powder
WO2012044155A1 (en) * 2010-09-28 2012-04-05 N.V. Nutricia Fat composition for programming immune response
EP2465507A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating skin diseases
BR112013016381A2 (en) 2010-12-29 2018-06-19 Abbott Lab food products including a new fat system containing monoglycerides
ES2708924T3 (en) 2010-12-31 2019-04-12 Abbott Lab Procedures for the use of oligosaccharides in human milk to improve respiratory health of the respiratory tract
EP2658400A2 (en) 2010-12-31 2013-11-06 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
CA3114006C (en) 2010-12-31 2023-07-25 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
MX338174B (en) 2010-12-31 2016-04-06 Abbott Lab Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents.
MX2013007692A (en) 2010-12-31 2013-08-15 Abbott Lab Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides.
MY191538A (en) 2010-12-31 2022-06-30 Abbott Lab Human milk oligosaccharides to promote growth of beneficial bacteria
WO2012112716A1 (en) * 2011-02-16 2012-08-23 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
FI124323B (en) * 2011-02-18 2014-06-30 Valio Oy Milk-based product and process for its preparation
WO2012133198A1 (en) * 2011-03-25 2012-10-04 イーエヌ大塚製薬株式会社 Nutritional composition for inflammatory diseases
JP5837315B2 (en) * 2011-03-25 2015-12-24 イーエヌ大塚製薬株式会社 Nutritional composition for inflammatory diseases
WO2012177118A1 (en) 2011-06-22 2012-12-27 N.V. Nutricia Method for reducing the occurrence of infection in young children
MY182335A (en) 2011-07-22 2021-01-19 Abbott Lab Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CN104023560A (en) 2011-08-29 2014-09-03 雅培制药有限公司 Human Milk Oligosaccharides For Preventing Injury And/Or Promoting Healing Of The Gastrointestinal Tract
CA2902788A1 (en) * 2013-03-27 2014-10-02 Ng Solutions Ltd. Nutritional supplement for growth enhancement
US20140328970A1 (en) * 2013-05-03 2014-11-06 Mead Johnson Nutrition Company Nutritional Composition Comprising Whey and Hydrolyzed Casein and Uses Thereof
DE202013008190U1 (en) 2013-09-17 2013-12-05 Pg Naturpharma Gmbh Preparation and its use in atopic dermatitis
EP2857410A1 (en) * 2013-10-04 2015-04-08 Jennewein Biotechnologie GmbH Process for purification of 2´-fucosyllactose using simulated moving bed chromatography
RU2697650C1 (en) * 2013-11-15 2019-08-16 Сосьете Де Продюи Нестле С.А. Compositions for preventing or treating allergies in infants born or fed by non-secretory mothers by providing fucosylated oligosaccharides, particularly infants at risk of or born by cesarean section
US20150157048A1 (en) * 2013-12-11 2015-06-11 Mead Johnson Nutrition Company Nutritional compositions containing stearidonic acid and uses thereof
WO2015154260A1 (en) * 2014-04-09 2015-10-15 Nestle (China) Ltd. Gender specific synthetic nutritional compositions and nutritional systems comprising them.
WO2015154257A1 (en) * 2014-04-09 2015-10-15 Nestle (China) Ltd. Gender specific synthetic nutritional compositions and, nutritional systems comprising them
WO2015154263A1 (en) * 2014-04-09 2015-10-15 Nestle (China) Ltd. Gender specific synthetic nutritional compositions and nutritional systems comprising them
WO2015154259A1 (en) * 2014-04-09 2015-10-15 Nestle (China) Ltd. Gender specific synthetic nutritional compositions and nutritional systems comprising them
WO2015154265A1 (en) * 2014-04-09 2015-10-15 Nestle (China) Ltd. Gender specific synthetic nutritional compositions and nutritional systems comprising them
WO2015154256A1 (en) * 2014-04-09 2015-10-15 Nestle (China) Ltd. Gender specific synthetic nutritional compositions and,nutritional systems comprising them
WO2015154254A1 (en) * 2014-04-09 2015-10-15 Nestle (China) Ltd. Gender specific synthetic nutritional compositions and nutritional systems comprising them
WO2015154251A1 (en) * 2014-04-09 2015-10-15 Nestle (China) Ltd. Gender specific synthetic nutritional compositions and nutritional systems comprising them.
CN107001528A (en) 2014-07-09 2017-08-01 米德瑞（美国）有限公司 Oligosaccharide composition and preparation method thereof
FR3029114B1 (en) * 2014-12-01 2017-01-13 United Pharmaceuticals INFANT NUTRITIONAL COMPOSITION FOR THE TREATMENT OF ATOPIC DERMATITIS AND ITS SYMPTOMS
MX2017009589A (en) 2015-01-26 2018-06-20 Kaleido Biosciences Inc Glycan therapeutics and related methods thereof.
WO2016122887A1 (en) 2015-01-26 2016-08-04 Midori Usa, Inc. Oligosaccharide compositions for use animal feed and methods of producing thereof
JP2018517677A (en) 2015-04-23 2018-07-05 カレイド・バイオサイエンシズ・インコーポレイテッド Glycan therapeutic agent and method
US10582714B2 (en) 2015-07-10 2020-03-10 Mead Johnson Nutrition Company Nutritional compositions and methods for promoting cognitive development
CN105231461A (en) * 2015-10-30 2016-01-13 中营康园（北京）科技有限公司 Body immunity-improving nutrient composition and application thereof
ES2638195B1 (en) * 2016-04-18 2018-08-02 Bioiberica, S.A. SKIN COMPOSITIONS
EP3703705B1 (en) 2017-11-03 2024-05-15 DSM Nutritional Products, LLC Glucose-containing glycan preparations for use in the treatment of hyperammonaemia
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
US12005083B1 (en) 2019-06-24 2024-06-11 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
US11849747B1 (en) 2019-06-24 2023-12-26 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
CN112933104B (en) * 2021-02-02 2021-12-14 陈玉松 New use of nucleotide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0483070A2 (en) 1990-10-24 1992-04-29 Sandoz Nutrition Ltd. Nutritionally complete feeding composition containing hydrolysed soluble fiber
AU2263800A (en) 1987-05-29 2000-06-08 Abbott Laboratories Nourishing products enriched with nucleosides and/or nucleotides for infants and adults and processes for their preparation
WO2001060378A2 (en) 2000-02-16 2001-08-23 N.V. Nutricia Antiadhesive carbohydrates
US20030054083A1 (en) 2000-12-13 2003-03-20 Sharon Gohman Infant formula with free amino acids and nucleotides

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61192245A (en) * 1985-02-21 1986-08-26 Snow Brand Milk Prod Co Ltd Powdery milk containing arginin
ES2007350A6 (en) * 1987-05-29 1989-06-16 Ganadera Union Ind Agro Food products enriched with nucleosides and/or nucleotides and preparation thereof.
DE568606T1 (en) 1991-01-24 1999-02-25 Martek Corp., Columbia, Md. MICROBIAL OILS AND THEIR USE
US5472952A (en) 1993-03-18 1995-12-05 Bristol-Myers Squibb Company Partially hydrolyzed pectin in nutritional compositions
DE4344342C2 (en) * 1993-12-23 1996-08-08 Milupa Ag Whey protein dominant infant formula
JP3419897B2 (en) * 1994-07-22 2003-06-23 明治乳業株式会社 Hypoallergenic formula
JP4034364B2 (en) * 1994-10-11 2008-01-16 雪印乳業株式会社 Antiallergic agent
ES2123903T5 (en) * 1995-08-04 2011-02-22 N.V. Nutricia NUTRITIVE COMPOSITION CONTAINING FIBER.
US5792501A (en) * 1996-04-15 1998-08-11 The Iams Company Queen's milk replacer
US5780081A (en) * 1996-10-28 1998-07-14 Nestec S.A. Fortification of food with calcium and process of making
JPH10262607A (en) * 1997-03-28 1998-10-06 Snow Brand Milk Prod Co Ltd Nutrient composition for infant
CA2285939C (en) 1997-04-11 2010-06-15 Calgene Llc Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants
US6288116B1 (en) * 1998-05-13 2001-09-11 Novartis Nutrition Ag Method of administration of a nutritional product to a person having renal failure
FR2781673B1 (en) * 1998-07-28 2001-09-28 Univ Picardie USE OF A GLUCURONANE AS AN IMMUNOSTIMULATING AGENT, METHOD OF PREPARATION
DE19836339B4 (en) 1998-08-11 2011-12-22 N.V. Nutricia carbohydrate mix
US6245379B1 (en) * 1998-09-30 2001-06-12 The Iams Company Method of administering a milk substitute to critical care animals
RU2275041C2 (en) * 1999-04-29 2006-04-27 Сосьете Де Продюи Нестле С.А. Composition of milk mixture, method for producing the same and milk mixture including composition (versions)
GB9923048D0 (en) * 1999-09-29 1999-12-01 Nestle Sa Composition comprising casein protein and whey protein
DE19958985A1 (en) * 1999-12-07 2001-06-13 Nutricia Nv Oligosaccharide mixture
US6630452B2 (en) * 2000-02-17 2003-10-07 Wyeth Nutritional formulation containing prebiotic substances
US20040143013A1 (en) 2000-02-28 2004-07-22 Bristol-Myers Squibb Company Use of docosahexaenoic acid and arachidonic acid enhancing the growth of preterm infants
US6420342B1 (en) * 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
DE10057976B4 (en) * 2000-11-22 2005-02-03 Südzucker AG Mannheim/Ochsenfurt Process for the preparation of pectin hydrolysis products
US6623954B1 (en) 2002-05-28 2003-09-23 Neose Technologies, Inc. Process for removal of phosphorous from a dairy stream
ES2649736T3 (en) 2002-06-28 2018-01-15 Nestec S.A. Therapeutic compositions for use in the prophylaxis or treatment of diarrhea
DK1733730T3 (en) 2003-10-24 2008-10-13 Nutricia Nv Immunomodulatory oligosaccharides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2263800A (en) 1987-05-29 2000-06-08 Abbott Laboratories Nourishing products enriched with nucleosides and/or nucleotides for infants and adults and processes for their preparation
EP0483070A2 (en) 1990-10-24 1992-04-29 Sandoz Nutrition Ltd. Nutritionally complete feeding composition containing hydrolysed soluble fiber
WO2001060378A2 (en) 2000-02-16 2001-08-23 N.V. Nutricia Antiadhesive carbohydrates
US20030054083A1 (en) 2000-12-13 2003-03-20 Sharon Gohman Infant formula with free amino acids and nucleotides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DONALD VOET; JUDITH G. VOET: "Biochemistry second edition", JOHN WILEY AND SONS, INC, pages: 849

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2241196A3 (en) * 2005-04-21 2010-11-17 N.V. Nutricia Nutritional supplement comprising oligosaccharides and cysteine for treating hiv
EP2356914A3 (en) * 2005-12-23 2014-01-01 N.V. Nutricia Composition for improving membrane composition and functioning of cells
WO2007073177A3 (en) * 2005-12-23 2008-07-17 Nutricia Nv Composition comprising polyunsaturated fatty acids for improving membrane composition
EP2359701B1 (en) 2005-12-23 2021-01-06 N.V. Nutricia Composition for improving membrane composition and functioning of cells for use in the treatment of allergy
EP2359701A1 (en) * 2005-12-23 2011-08-24 N.V. Nutricia Composition for improving membrane composition and functioning of cells
WO2007073177A2 (en) * 2005-12-23 2007-06-28 N.V. Nutricia Composition comprising polyunsaturated fatty acids for improving membrane composition
JP2007222128A (en) * 2006-02-27 2007-09-06 Pola Chem Ind Inc Food composition
WO2007114696A1 (en) * 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
US8754064B2 (en) 2006-03-30 2014-06-17 N.V. Nutricia Milk oligosaccharide for stimulating the immune system
EP2117355B1 (en) 2007-03-13 2017-04-26 N.V. Nutricia Method of improving skills with a composition comprising non-digestible saccharide
US20140187513A1 (en) * 2007-03-13 2014-07-03 N.V. Nutricia Method of improving skills with a composition comprising non-digestible saccharide
RU2475031C2 (en) * 2007-05-18 2013-02-20 Мид Джонсон Нутришен Компани Acidified liquid additive to human milk
US10251899B2 (en) * 2007-10-08 2019-04-09 Mead Johnson Nutrition Company Method for improving stool characteristics in infants
EP2211629B1 (en) 2007-10-19 2020-07-08 Fonterra Co-Operative Group Limited Methods of maintaining or increasing growth or cognitive development
US20110009349A1 (en) * 2007-10-19 2011-01-13 Fonterra Co-Operative Group Limited Methods of maintaining or increasing growth or cognitive development
EP2798963A1 (en) 2010-04-26 2014-11-05 Enzymotec Ltd. Use of a lipid composition for reducing the frequency and duration of crying periods in an infant
US9433599B2 (en) 2010-04-26 2016-09-06 Enzymotec Ltd. Methods and lipid compositions for promoting development of gut flora
WO2011135564A1 (en) 2010-04-26 2011-11-03 Enzymotec Ltd. Methods and lipid compositions for promoting development of gut flora
WO2012092153A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
EP2658399B1 (en) 2010-12-31 2019-02-27 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides for use in treating and/or preventing enteric rotavirus infection

Also Published As

Publication number Publication date
US8114441B2 (en) 2012-02-14
CN101766228A (en) 2010-07-07
UA88918C2 (en) 2009-12-10
US20100136134A1 (en) 2010-06-03
JP4965444B2 (en) 2012-07-04
EP1781307A2 (en) 2007-05-09
RU2007110174A (en) 2008-09-27
CA2577698A1 (en) 2006-02-23
US20120195975A1 (en) 2012-08-02
NZ553299A (en) 2010-09-30
AU2005274266A1 (en) 2006-02-23
RU2007110173A (en) 2008-09-27
CN101039686A (en) 2007-09-19
EP1634599A1 (en) 2006-03-15
CN101048167A (en) 2007-10-03
BRPI0514498A (en) 2008-06-10
ATE427112T1 (en) 2009-04-15
EP1781307B1 (en) 2009-04-01
ES2322380T3 (en) 2009-06-19
JP2008510697A (en) 2008-04-10
PL1781307T3 (en) 2009-08-31
WO2006018314A2 (en) 2006-02-23
US8580316B2 (en) 2013-11-12
BRPI0514526A (en) 2008-06-10
EP1781306A2 (en) 2007-05-09
NZ553248A (en) 2009-12-24
AU2005273099B2 (en) 2011-08-18
AU2005274266B2 (en) 2011-03-10
WO2006019300A3 (en) 2006-06-01
DE602005013679D1 (en) 2009-05-14
CN101766228B (en) 2013-05-08
RU2404785C2 (en) 2010-11-27
JP2008510689A (en) 2008-04-10
RU2426549C2 (en) 2011-08-20
AU2005273099A1 (en) 2006-02-23
CA2576042A1 (en) 2006-02-23
WO2006018314A3 (en) 2006-06-29
US20080125346A1 (en) 2008-05-29
CA2576042C (en) 2017-07-04

Similar Documents

Publication Publication Date Title
AU2005273099B2 (en) Immune stimulatory infant nutrition
US11090321B2 (en) Mixture of non-digestible oligosaccharides for stimulating the immune system
EP2453901B1 (en) Fucosyllactose as breast milk identical non-digestible oligosaccharide for treating and/or preventing viral infections
AU2006323322B2 (en) Composition containing oligosaccharides for the treatment / prevention of infections
TW201438719A (en) Human milk oligosaccharides to ameliorate symptoms of stress
TW201429410A (en) Neuroprotective dietary oligosaccharides
TW201438720A (en) Dietary oligosaccharides to enhance learning and memory
EP2428125B1 (en) Nutritional formulation with high energy content
CA3198961A1 (en) Synthetic compositions comprising lnfp iii and lsta

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005273099

Country of ref document: AU

Ref document number: 2005775170

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007527084

Country of ref document: JP

Ref document number: 553299

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2577698

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1672/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005273099

Country of ref document: AU

Date of ref document: 20050822

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1200700585

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2007110173

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200580035168.5

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005775170

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11573939

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0514498

Country of ref document: BR